need-greed theory of innovation is patently false constant pharma shenanigans have proved we'd be fools to trust them

As our HA Blog post states, I'm skeptical that method of treatment (MoT, aka method of use) patents in pharma add much value. While MoT patents spur preclinical and clinical development of new therapeutic uses, they are also an evergreening tactic. /3 http

RT @cmrherder: Secondary patents are a HUGE part of drug pricing problem | See this key paper in @PLOSONE https://t.co/WFE3IHILhe https://t…

Secondary patents are a HUGE part of drug pricing problem | See this key paper in @PLOSONE https://t.co/WFE3IHILhe https://t.co/qZdFVBsdfX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Reading up on #patents and ‘ever greening’. Just came across this useful article. @akapczynski @FixPatentLaw http://t.co/1GZ01CuXXX

Superb empirical piece on the perils of secondary drug patenting and access to medicine - open access and online: http://t.co/rN1Dr6lF7r

Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents http://t.co/3yy0TIId

Now there is evidence that late-filed independent secondary patents are more common for bestselling drugs: PLOS article http://t.co/ypaYoZLb

Nice plos one paper on secondary patenting by Park, Sampat and Kapczynski http://t.co/KuSN7DL1 @fixpatentlaw @msf_access @TAC

Nice plos one paper on secondary patenting by Park, Sampat and Kapczynski http://t.co/KuSN7DL1 @fixpatentlaw @msf_access @TAC

Now there is evidence that late-filed independent secondary patents are more common for bestselling drugs: PLOS article http://t.co/ypaYoZLb

Major costs if countries trade away ability to limit what's patentable, smart analysis @akapczynski http://t.co/3X8TbuGp

Countries should not trade away their rights to limit what can be patented: smart analysis @akapczynski http://t.co/3X8TbuGp

Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents - http://t.co/xNA6T6G4